{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:21:01Z","timestamp":1777494061301,"version":"3.51.4"},"reference-count":178,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1UH3DA047711-03"],"award-info":[{"award-number":["1UH3DA047711-03"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1UG3DA057439-01"],"award-info":[{"award-number":["1UG3DA057439-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1UG3DA056247-01"],"award-info":[{"award-number":["1UG3DA056247-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"National Institute on Drug Abuse Intramural Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jpet.2025.103709","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T09:24:05Z","timestamp":1757755445000},"page":"103709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nonpharmacological and pharmacological influences on opioid effects: A review of clinical research findings"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3404-766X","authenticated-orcid":false,"given":"Rachel","family":"Luba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103709_bib12","series-title":"Words Matter: Preferred Language for Talking About Addiction","year":"2021"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2009.10.010","article-title":"Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms","volume":"21","author":"Kelly","year":"2010","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jpet.2025.103709_bib4","unstructured":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. Published online 2023."},{"key":"10.1016\/j.jpet.2025.103709_bib5","series-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","year":"2024"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1901\/jeab.2006.23-06","article-title":"Behavioral determinants of drug action: the contributions of Peter B. Dews","volume":"86","author":"Barrett","year":"2006","journal-title":"J Exp Anal Behav"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-3565(25)11525-5","article-title":"Studies on behavior. I. Differential sensitivity to pentobarbital of pecking performance in pigeons depending on the schedule of reward","volume":"113","author":"Dews","year":"1955","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0022-3565(25)11620-0","article-title":"Studies on behavior. II. The effects of pentobarbital, methamphetamine and scopolamine on performances in pigeons involving discriminations","volume":"115","author":"Dews","year":"1955","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1749-6632.1956.tb49639.x","article-title":"Modification by drugs of performance on simple schedules of positive reinforcement","volume":"65","author":"Dews","year":"1956","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0022-3565(25)11873-9","article-title":"Studies on behavior. III. Effects of scopolamine on reversal of a discriminatory performance in pigeons","volume":"119","author":"Dews","year":"1957","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1901\/jeab.1969.12-191","article-title":"Studies on responding under fixed-interval schedules of reinforcement: the effects on the pattern of responding of changes in requirements at reinforcement","volume":"12","author":"Dews","year":"1969","journal-title":"J Exp Anal Behav"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-012-2954-z","article-title":"The drug effects questionnaire: psychometric support across three drug types","volume":"227","author":"Morean","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.jpet.2025.103709_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jps.3030440603","article-title":"Some pharmacological properties of phenyl alpha-naphthyl ketimine","volume":"44","author":"Headlee","year":"1955","journal-title":"J Am Pharm Assoc Am Pharm Assoc"},{"issue":"12","key":"10.1016\/j.jpet.2025.103709_bib14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/jps.3030451206","article-title":"Drug addiction I. Addiction by escape training","volume":"45","author":"Coppock","year":"1956","journal-title":"J Am Pharm Assoc Am Pharm Assoc"},{"issue":"3537","key":"10.1016\/j.jpet.2025.103709_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.138.3537.143","article-title":"Experimental morphine addiction: method for automatic intravenous injections in unrestrained rats","volume":"138","author":"Weeks","year":"1962","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00413156","article-title":"Factors affecting voluntary morphine intake in self-maintained addicted rats","volume":"6","author":"Weeks","year":"1964","journal-title":"Psychopharmacologia"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2008.03.001","article-title":"The role of human drug self-administration procedures in the development of medications","volume":"96","author":"Comer","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"5\u20136","key":"10.1016\/j.jpet.2025.103709_bib18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/FBP.0b013e3283641c3d","article-title":"A review of human drug self-administration procedures","volume":"24","author":"Jones","year":"2013","journal-title":"Behav Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0022-3565(25)20504-3","article-title":"The reinforcing and subjective effects of morphine in post-addicts: a dose-response study","volume":"259","author":"Lamb","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.npp.1301083","article-title":"Heroin-induced reinstatement is specific to compulsive heroin use and dissociable from heroin reward and sensitization","volume":"32","author":"Lenoir","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.jpet.2025.103709_bib21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neubiorev.2003.11.007","article-title":"Neurobiological mechanisms in the transition from drug use to drug dependence","volume":"27","author":"Koob","year":"2004","journal-title":"Neurosci Biobehav Rev"},{"issue":"12","key":"10.1016\/j.jpet.2025.103709_bib22","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1360-0443.2007.02011.x","article-title":"Self-administration of drugs in animals and humans as a model and an investigative tool","volume":"102","author":"Panlilio","year":"2007","journal-title":"Addiction"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103709_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00213-002-1193-0","article-title":"Reinstatement of punishment-suppressed opioid self-administration in rats: an alternative model of relapse to drug abuse","volume":"168","author":"Panlilio","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0893-133X(99)00133-5","article-title":"Persistent increase in the motivation to take heroin in rats with a history of drug escalation","volume":"22","author":"Ahmed","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpet.2025.103709_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pbb.2017.04.006","article-title":"Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: implications for negative reinforcement as a driver of addiction and target for medications development","volume":"164","author":"Negus","year":"2018","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpet.2025.103709_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2022.100057","article-title":"Extended access to fentanyl vapor self-administration leads to addiction-like behaviors in mice: Blood chemokine\/cytokine levels as potential biomarkers","volume":"5","author":"Marchette","year":"2023","journal-title":"Addict Neurosci"},{"issue":"18","key":"10.1016\/j.jpet.2025.103709_bib28","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1111\/bph.15520","article-title":"Paradoxical changes in brain reward status during oxycodone self-administration in a novel test of the negative reinforcement hypothesis","volume":"178","author":"Nguyen","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103709_bib29","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1038\/sj.npp.1301008","article-title":"Unlimited access to heroin self-administration: independent motivational markers of opiate dependence","volume":"31","author":"Chen","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"13","key":"10.1016\/j.jpet.2025.103709_bib30","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1111\/bph.70023","article-title":"Behavioural and pharmacokinetic analysis of heroin and cocaine self-administration: effects of timeout on self-administration and choice in male rats","volume":"182","author":"D\u2019Ottavio","year":"2025","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103709_bib31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/bph.15791","article-title":"Increased heroin intake and relapse vulnerability in intermittent relative to continuous self-administration: sex differences in rats","volume":"180","author":"D\u2019Ottavio","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00213-020-05750-2","article-title":"A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse","volume":"238","author":"Bakhti-Suroosh","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpet.2025.103709_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF01568465","article-title":"A psychodynamic study of a patient during experimental self-regulated readdiction to morphine","volume":"26","author":"Wikler","year":"1952","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.jpet.2025.103709_bib34","series-title":"The Heroin Stimulus","author":"Meyer","year":"1979"},{"issue":"4431","key":"10.1016\/j.jpet.2025.103709_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.7352279","article-title":"Buprenorphine suppresses heroin use by heroin addicts","volume":"207","author":"Mello","year":"1980","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib36","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1124\/jpet.105.090423","article-title":"Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin abusers","volume":"315","author":"Comer","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib37","first-page":"7","article-title":"Efficacy of morphine versus fentanyl patient-controlled analgesia for postoperative pain management in colorectal surgery","volume":"2025","author":"Saad Eddin","year":"2025","journal-title":"Qatar Med J"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0304-3959(94)00255-D","article-title":"The influence of lockout intervals and drug selection on patient-controlled analgesia following gynecological surgery","volume":"62","author":"Ginsberg","year":"1995","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0952-8180(96)00077-3","article-title":"Effect of varying intravenous patient-controlled analgesia dose and lockout interval while maintaining a constant hourly maximum dose","volume":"8","author":"Badner","year":"1996","journal-title":"J Clin Anesth"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1037\/1064-1297.13.1.3","article-title":"Opioid craving and seeking behavior in physically dependent volunteers: effects of acute withdrawal and drug reinforcement opportunity","volume":"13","author":"Greenwald","year":"2005","journal-title":"Exp Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib41","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1124\/jpet.301.2.698","article-title":"Relative reinforcing effects of three opioids with different durations of action","volume":"301","author":"Ko","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00008877-199000140-00003","article-title":"Models of relative reinforcing efficacy of drugs and their predictive utility","volume":"1","author":"Katz","year":"1990","journal-title":"Behav Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0376-8716(96)01274-4","article-title":"The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers","volume":"42","author":"Zacny","year":"1996","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib44","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/02791072.2018.1508789","article-title":"The PPAR\u03b3 agonist pioglitazone fails to alter the abuse potential of heroin, but does reduce heroin craving and anxiety","volume":"50","author":"Jones","year":"2018","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hec.2902","article-title":"Can price get the monkey off our back? A meta-analysis of illicit drug demand","volume":"23","author":"Gallet","year":"2014","journal-title":"Health Econ"},{"key":"10.1016\/j.jpet.2025.103709_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2024.173803","article-title":"Human laboratory models of reward in substance use disorder","volume":"241","author":"Johansen","year":"2024","journal-title":"Pharmacol Biochem Behav"},{"issue":"6\u20137","key":"10.1016\/j.jpet.2025.103709_bib47","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00008877-199911000-00009","article-title":"A comparison of measures of relative reinforcing efficacy and behavioral economics: cigarettes and money in smokers","volume":"10","author":"Bickel","year":"1999","journal-title":"Behav Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1901\/jeab.1999.72-299","article-title":"Similar consumption and responding across single and multiple sources of drug","volume":"72","author":"Bickel","year":"1999","journal-title":"J Exp Anal Behav"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib49","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1037\/1064-1297.7.4.412","article-title":"Modeling drug consumption in the clinic using simulation procedures: Demand for heroin and cigarettes in opioid-dependent outpatients","volume":"7","author":"Jacobs","year":"1999","journal-title":"Exp Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib50","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0005-7894(98)80050-6","article-title":"The price of change: the behavioral economics of drug dependence","volume":"29","author":"Bickel","year":"1998","journal-title":"Behav Ther"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002130050325","article-title":"A comparison of progressive ratio schedules versus behavioral economic measures: effect of an alternative reinforcer on the reinforcing efficacy of phencyclidine","volume":"132","author":"Rodefer","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s002130050956","article-title":"Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans","volume":"143","author":"Comer","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib53","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib54","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphine\/naloxone in opioid-dependent humans","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-010-1898-4","article-title":"Acute effects of intramuscular and sublingual buprenorphine and buprenorphine\/naloxone in non-dependent opioid abusers","volume":"211","author":"Duke","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.jpet.2025.103709_bib57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.pbb.2014.04.012","article-title":"The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users","volume":"122","author":"Jones","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"issue":"Suppl 1","key":"10.1016\/j.jpet.2025.103709_bib58","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.drugalcdep.2006.01.016","article-title":"Development of opioid formulations with limited diversion and abuse potential","volume":"83","author":"Fudala","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"2 Suppl","key":"10.1016\/j.jpet.2025.103709_bib59","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0376-8716(03)00057-7","article-title":"Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?","volume":"70","author":"Mendelson","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpet.2025.103709_bib60","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.drugalcdep.2017.06.033","article-title":"Abuse liability of intravenous buprenorphine vs. buprenorphine\/naloxone: importance of absolute naloxone amount","volume":"179","author":"Jones","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.biopsycho.2006.01.010","article-title":"Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol","volume":"73","author":"Epstein","year":"2006","journal-title":"Biol Psychol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0376-8716(91)90081-9","article-title":"Abuse potential and pharmacological comparison of tramadol and morphine","volume":"27","author":"Preston","year":"1991","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpet.2025.103709_bib63","first-page":"515","article-title":"Evaluation of the 5HT3 antagonist ondansetron (O) for cocaine (C)-like activity and abuse potential","volume":"105","author":"Jasinski","year":"1990","journal-title":"NIDA Res Monogr"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103709_bib64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.drugalcdep.2012.09.018","article-title":"Abuse liability and reinforcing efficacy of oral tramadol in humans","volume":"129","author":"Babalonis","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib65","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jpba.2007.04.012","article-title":"Improved liquid chromatographic method for the simultaneous determination of tramadol and its three main metabolites in human plasma, urine and saliva","volume":"44","author":"Ardakani","year":"2007","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib66","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1213\/01.ane.0000189613.61910.32","article-title":"The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6","volume":"102","author":"Enggaard","year":"2006","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib67","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/adb.12173","article-title":"Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiological effects in humans","volume":"21","author":"Babalonis","year":"2016","journal-title":"Addict Biol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00126839-200506020-00004","article-title":"Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets","volume":"6","author":"Adams","year":"2005","journal-title":"Drugs R D"},{"issue":"6","key":"10.1016\/j.jpet.2025.103709_bib69","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00007691-199212000-00008","article-title":"Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration","volume":"14","author":"Leow","year":"1992","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.jpet.2025.103709_bib70","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","article-title":"The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects","volume":"33","author":"P\u00f6yhi\u00e4","year":"1992","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","article-title":"Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment","volume":"14","author":"Butler","year":"2013","journal-title":"J Pain"},{"issue":"6","key":"10.1016\/j.jpet.2025.103709_bib72","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/j.pain.0000000000000511","article-title":"A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs","volume":"157","author":"Cicero","year":"2016","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.jpet.2025.103709_bib74","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s00213-021-05872-1","article-title":"Relative potency of intravenous oxymorphone compared to other \u03bc opioid agonists in humans\u2014pilot study outcomes","volume":"238","author":"Babalonis","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib75","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s002130000624","article-title":"Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans","volume":"154","author":"Abreu","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5055\/jom.2009.0022","article-title":"Relationship between rate of infusion and reinforcing strength of oxycodone in humans","volume":"5","author":"Comer","year":"2009","journal-title":"J Opioid Manag"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s002130050702","article-title":"Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review","volume":"139","author":"Stafford","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib78","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1476-5381.1977.tb07533.x","article-title":"The animal pharmacology of buprenorphine, an oripavine analgesic agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib79","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1476-5381.1981.tb10473.x","article-title":"In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions","volume":"74","author":"Dum","year":"1981","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.jcp.0000138766.15858.c6","article-title":"Effects of high-dose intravenous buprenorphine in experienced opioid abusers","volume":"24","author":"Umbricht","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib81","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0022-3565(25)09651-X","article-title":"Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure","volume":"273","author":"Walker","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib82","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/npp.2010.172","article-title":"The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine\/naloxone","volume":"36","author":"Jones","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib83","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2008.05.007","article-title":"The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers","volume":"98","author":"Walsh","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib84","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00213-010-1942-4","article-title":"Intravenous oxycodone, hydrocodone and morphine in recreational opioid users: abuse potential and relative potencies","volume":"212","author":"Stoops","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib85","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.npp.1301479","article-title":"Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers","volume":"33","author":"Comer","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/FBP.0b013e3283536d6f","article-title":"Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers","volume":"23","author":"Cooper","year":"2012","journal-title":"Behav Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib87","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF00451687","article-title":"Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine","volume":"98","author":"Lett","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib88","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.pbb.2005.01.003","article-title":"Morphine preexposure facilitates morphine place preference and attenuates morphine taste aversion","volume":"80","author":"Simpson","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"issue":"11","key":"10.1016\/j.jpet.2025.103709_bib89","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41386-020-0679-y","article-title":"Opioid dose regimen shapes mesolimbic adaptations","volume":"45","author":"Cahill","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.jpet.2025.103709_bib90","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41386-020-0643-x","article-title":"Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system","volume":"45","author":"Lefevre","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"13","key":"10.1016\/j.jpet.2025.103709_bib91","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1038\/s41386-018-0211-9","article-title":"The gut microbiota mediates reward and sensory responses associated with regimen-selective morphine dependence","volume":"43","author":"Lee","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpet.2025.103709_bib92","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpsychires.2014.08.009","article-title":"Continuous infusion versus intermittent bolus dosing of morphine: a comparison of analgesia, tolerance, and subsequent voluntary morphine intake","volume":"59","author":"Yu","year":"2014","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jpet.2025.103709_bib93","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02245446","article-title":"Opioid physical dependence development: effects of single versus repeated morphine pretreatments and of subjects\u2019 opioid exposure history","volume":"114","author":"Azorlosa","year":"1994","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00008877-200002000-00010","article-title":"Alternative reinforcers differentially modify cocaine self-administration by humans","volume":"11","author":"Hart","year":"2000","journal-title":"Behav Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib95","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.pnpbp.2011.10.003","article-title":"Alternative reinforcer response cost impacts cocaine choice in humans","volume":"36","author":"Stoops","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jpet.2025.103709_bib96","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jhealeco.2015.01.008","article-title":"The price elasticity of demand for heroin: matched longitudinal and experimental evidence","volume":"41","author":"Olmstead","year":"2015","journal-title":"J Health Econ"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103709_bib97","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.drugalcdep.2009.04.006","article-title":"Behavioral economic analysis of opioid consumption in heroin-dependent individuals: effects of alternative reinforcer magnitude and post-session drug supply","volume":"104","author":"Greenwald","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"10.1016\/j.jpet.2025.103709_bib98","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00008877-199712000-00002","article-title":"Choice between money and intranasal heroin in morphine-maintained humans","volume":"8","author":"Comer","year":"1997","journal-title":"Behav Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib99","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/clpt.1983.124","article-title":"Oral methadone self-administration: effects of dose and alternative reinforcers","volume":"34","author":"Stitzer","year":"1983","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1037\/a0028327","article-title":"Intranasal oxycodone self-administration in non-dependent opioid abusers","volume":"20","author":"Middleton","year":"2012","journal-title":"Exp Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib101","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.pbb.2007.01.008","article-title":"Gender and stimulus difference in cue-induced responses in abstinent heroin users","volume":"86","author":"Yu","year":"2007","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib102","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1360-0443.1999.9433273.x","article-title":"Meta-analysis of cue-reactivity in addiction research","volume":"94","author":"Carter","year":"1999","journal-title":"Addiction"},{"issue":"1\u20133","key":"10.1016\/j.jpet.2025.103709_bib103","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejphar.2009.05.011","article-title":"Effect of rapamycin on cue-induced drug craving in abstinent heroin addicts","volume":"615","author":"Shi","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103709_bib104","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.addbeh.2014.04.007","article-title":"Laboratory-induced cue reactivity among individuals with prescription opioid dependence","volume":"39","author":"Back","year":"2014","journal-title":"Addict Behav"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib105","first-page":"178","article-title":"Craving by imagery cue reactivity in opiate dependence following detoxification","volume":"45","author":"Behera","year":"2003","journal-title":"Indian J Psychiatry"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib106","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2009.07.016","article-title":"Reactivity to laboratory stress provocation predicts relapse to cocaine","volume":"106","author":"Back","year":"2010","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib107","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1360-0443.1986.tb00385.x","article-title":"Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction","volume":"81","author":"Childress","year":"1986","journal-title":"Br J Addict"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0740-5472(86)90018-8","article-title":"Conditioned responses in a methadone population. A comparison of laboratory, clinic, and natural settings","volume":"3","author":"Childress","year":"1986","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"10.1016\/j.jpet.2025.103709_bib109","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.biopsych.2011.05.015","article-title":"Cue-induced reactivity, cortisol response and substance use outcome in treated heroin dependent individuals","volume":"70","author":"Fatseas","year":"2011","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0740-5472(98)00004-X","article-title":"Cue reactivity and effects of cue exposure in abstinent posttreatment drug users","volume":"16","author":"Franken","year":"1999","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"10.1016\/j.jpet.2025.103709_bib111","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1176\/appi.ajp.158.10.1680","article-title":"Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects","volume":"158","author":"Daglish","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib112","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0376-8716(99)00158-1","article-title":"Neural responses associated with cue evoked emotional states and heroin in opiate addicts","volume":"60","author":"Sell","year":"2000","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20133","key":"10.1016\/j.jpet.2025.103709_bib113","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugalcdep.2008.07.012","article-title":"Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males","volume":"99","author":"Zijlstra","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000097968","article-title":"Cue exposure therapy for the treatment of opiate addiction: results of a randomized controlled clinical trial","volume":"76","author":"Marissen","year":"2007","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.jpet.2025.103709_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107859","article-title":"Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder","volume":"208","author":"Brandt","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-8703(36)90370-8","article-title":"The cold pressor test for measuring the reactibility of the blood pressure: Data concerning 571 normal and hypertensive subjects","volume":"11","author":"Hines","year":"1936","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib117","first-page":"41","article-title":"Relationship between plasma morphine concentrations and pharmacologic effects in postoperative patients using patient-controlled analgesia","volume":"4","author":"Graves","year":"1985","journal-title":"Clin Pharm"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib118","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(90)90011-9","article-title":"Simplified postoperative patient-controlled analgesia on a gynecologic oncology service","volume":"38","author":"Berman","year":"1990","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103709_bib119","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2044.1990.tb14624.x","article-title":"Long-term patient-controlled analgesia in children","volume":"45","author":"Mowbray","year":"1990","journal-title":"Anaesthesia"},{"issue":"14","key":"10.1016\/j.jpet.2025.103709_bib120","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jama.1991.03470140059024","article-title":"Patient-controlled analgesia: does a concurrent opioid infusion improve pain management after surgery?","volume":"266","author":"Parker","year":"1991","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib121","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3959(95)00088-7","article-title":"Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers","volume":"64","author":"Borgbjerg","year":"1996","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib122","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s002130050298","article-title":"Modulating effects of a cold water stimulus on opioid effects in volunteers","volume":"131","author":"Conley","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"issue":"1\u20133","key":"10.1016\/j.jpet.2025.103709_bib123","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.drugalcdep.2009.12.018","article-title":"Abuse liability of oxycodone as a function of pain and drug use history","volume":"109","author":"Comer","year":"2010","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib124","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/s0304-3959(02)00349-4","article-title":"The \u03bc-opioid agonist remifentanil attenuates hyperalgesia evoked by blunt and punctuated stimuli with different potency: a pharmacological evaluation of the freeze lesion in humans","volume":"102","author":"L\u00f6tsch","year":"2003","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/bja\/85.4.529","article-title":"Remifentanil inhibits muscular more than cutaneous pain in humans","volume":"85","author":"Curatolo","year":"2000","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib126","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0091270002042001008","article-title":"Concentration-effect relationships for intravenous alfentanil and ketamine infusions in human volunteers: effects on acute thresholds and capsaicin-evoked hyperpathia","volume":"42","author":"Wallace","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib127","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pain.2006.02.006","article-title":"A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model","volume":"123","author":"Staahl","year":"2006","journal-title":"Pain"},{"issue":"8","key":"10.1016\/j.jpet.2025.103709_bib128","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1034\/j.1399-6576.2003.00204.x","article-title":"Pharmacological modulation of experimental phasic and tonic muscle pain by morphine, alfentanil and ketamine in healthy volunteers","volume":"47","author":"Schulte","year":"2003","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.jpet.2025.103709_bib129","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psyneuen.2014.12.004","article-title":"Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans","volume":"52","author":"Bershad","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jpet.2025.103709_bib130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ynstr.2016.11.001","article-title":"The trier social stress test: principles and practice","volume":"6","author":"Allen","year":"2016","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.jpet.2025.103709_bib131","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yhbeh.2018.04.009","article-title":"Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans","volume":"102","author":"Bershad","year":"2018","journal-title":"Horm Behav"},{"key":"10.1016\/j.jpet.2025.103709_bib132","article-title":"Stress-enhanced opioid self-administration in healthy men: a randomized controlled experimental medicine study","author":"Eikemo","year":"2023","journal-title":"OSF"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib133","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1526-4637.2007.00370.x","article-title":"What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse\/addiction and\/or aberrant drug-related behaviors? A structured evidence-based review","volume":"9","author":"Fishbain","year":"2008","journal-title":"Pain Med"},{"issue":"12","key":"10.1016\/j.jpet.2025.103709_bib134","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.pain.2013.07.046","article-title":"Addictive behaviors related to opioid use for chronic pain: a population-based study","volume":"154","author":"H\u00f8jsted","year":"2013","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib135","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.annemergmed.2019.04.019","article-title":"Risk factors for misuse of prescribed opioids: a systematic review and meta-analysis","volume":"74","author":"Cragg","year":"2019","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jpet.2025.103709_bib136","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2147\/JPR.S131979","article-title":"Factors associated with prescription opioid misuse in a cross-sectional cohort of patients with chronic non-cancer pain","volume":"10","author":"Hah","year":"2017","journal-title":"J Pain Res"},{"issue":"8","key":"10.1016\/j.jpet.2025.103709_bib137","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.pain.2013.05.004","article-title":"Buprenorphine\/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone","volume":"154","author":"Roux","year":"2013","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib138","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpain.2013.09.014","article-title":"The association between negative affect and prescription opioid misuse in patients with chronic pain: the mediating role of opioid craving","volume":"15","author":"Martel","year":"2014","journal-title":"J Pain"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib139","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/ALN.0000000000000768","article-title":"Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain","volume":"123","author":"Wasan","year":"2015","journal-title":"Anesthesiology"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103709_bib140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.drugalcdep.2013.02.034","article-title":"Catastrophic thinking and increased risk for prescription opioid misuse in patients with chronic pain","volume":"132","author":"Martel","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib141","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/AJP.0b013e3180330dc5","article-title":"Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain","volume":"23","author":"Wasan","year":"2007","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpet.2025.103709_bib142","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.copsyc.2015.03.020","article-title":"Chronic pain, negative affect, and prescription opioid abuse","volume":"5","author":"Jurcik","year":"2015","journal-title":"Curr Opin Psychol"},{"key":"10.1016\/j.jpet.2025.103709_bib143","article-title":"Using ecological momentary assessments of negative affect and craving during residential opioid use disorder treatment to predict patients\u2019 relapse to substance use","volume":"146","author":"Cleveland","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"9","key":"10.1016\/j.jpet.2025.103709_bib144","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-018-4966-9","article-title":"Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder","volume":"235","author":"Preston","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib145","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/10550887.2011.581985","article-title":"Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals","volume":"30","author":"Carcoba","year":"2011","journal-title":"J Addict Dis"},{"issue":"10","key":"10.1016\/j.jpet.2025.103709_bib146","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1037\/ccp0000402","article-title":"Concurrent and lagged associations of prescription opioid use with pain and negative affect in the daily lives of chronic pain patients","volume":"87","author":"Carpenter","year":"2019","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib147","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1037\/1064-1297.16.5.429","article-title":"Retrospective accounts of initial subjective effects of opioids in patients treated for pain who do or do not develop opioid addiction: a pilot case-control study","volume":"16","author":"Bieber","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.jpet.2025.103709_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112644","article-title":"Inter-individual divergence in thresholds for detecting opioid effects: within-subject human laboratory evidence of a testable behavioral phenotype","volume":"271","author":"McKendrick","year":"2025","journal-title":"Drug Alcohol Depend"},{"issue":"43","key":"10.1016\/j.jpet.2025.103709_bib149","doi-asserted-by":"crossref","first-page":"17705","DOI":"10.1073\/pnas.1120201109","article-title":"Baseline reward circuitry activity and trait reward responsiveness predict expression of opioid analgesia in healthy subjects","volume":"109","author":"Wanigasekera","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib150","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12680","article-title":"Preliminary evidence of different and clinically-meaningful opioid withdrawal phenotypes","volume":"25","author":"Dunn","year":"2020","journal-title":"Addict Biol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib151","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1526-4637.2012.01368.x","article-title":"Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS)","volume":"13","author":"Blick","year":"2012","journal-title":"Pain Med"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib152","first-page":"69","article-title":"Opioid-induced hypogonadism in palliative care. Does it matter? Report on four patients treated with hormone substitution","volume":"8","author":"Roantree","year":"2009","journal-title":"Adv Palliat Med"},{"key":"10.1016\/j.jpet.2025.103709_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104522","article-title":"Sex differences in opioid receptor mediated effects: Role of androgens","volume":"134","author":"Sharp","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib154","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.pbb.2004.01.021","article-title":"The effects of a cold-water stimulus on butorphanol effects in males and females","volume":"78","author":"Zacny","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pain.2010.06.012","article-title":"Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies","volume":"151","author":"Niesters","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.jpet.2025.103709_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104447","article-title":"Sex differences in the response to opioids for pain relief: a systematic review and meta-analysis","volume":"148","author":"Pisanu","year":"2019","journal-title":"Pharmacol Res"},{"issue":"1\u20133","key":"10.1016\/j.jpet.2025.103709_bib157","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.drugalcdep.2011.11.018","article-title":"Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusers","volume":"123","author":"Lofwall","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"20","key":"10.1016\/j.jpet.2025.103709_bib158","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172886","article-title":"An emerging multi-omic understanding of the genetics of opioid addiction","volume":"134","author":"Johnson","year":"2024","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.jpet.2025.103709_bib159","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1601-183X.2008.00410.x","article-title":"Genetic susceptibility to heroin addiction: a candidate gene association study","volume":"7","author":"Levran","year":"2008","journal-title":"Genes Brain Behav"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib160","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ajmg.b.30264","article-title":"The effect of dopamine D2, D5 receptor and transporter (SLC6A3) polymorphisms on the cue-elicited heroin craving in Chinese","volume":"141B","author":"Li","year":"2006","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"Suppl 7","key":"10.1016\/j.jpet.2025.103709_bib161","first-page":"007","article-title":"Analyzing interaction of \u03bc-, \u03b4- and \u03ba-opioid receptor gene variants on alcohol or drug dependence using a pattern discovery-based method","author":"Li","year":"2013","journal-title":"J Addict Res Ther"},{"issue":"5","key":"10.1016\/j.jpet.2025.103709_bib162","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.mp.4002035","article-title":"The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk","volume":"13","author":"Zhang","year":"2008","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib163","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/tpj.2013.30","article-title":"Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European American females","volume":"14","author":"Clarke","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib164","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1369-1600.2012.00445.x","article-title":"Association of OPRD1 polymorphisms with heroin dependence in a large case-control series","volume":"19","author":"Nelson","year":"2014","journal-title":"Addict Biol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib166","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13355","article-title":"Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: a human laboratory phenotype-genotype assessment","volume":"29","author":"Dunn","year":"2024","journal-title":"Addict Biol"},{"key":"10.1016\/j.jpet.2025.103709_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172778","article-title":"Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone","volume":"186","author":"Jones","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib168","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ajad.12316","article-title":"Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms","volume":"25","author":"Jones","year":"2016","journal-title":"Am J Addict"},{"issue":"4","key":"10.1016\/j.jpet.2025.103709_bib169","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"issue":"6","key":"10.1016\/j.jpet.2025.103709_bib171","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00004714-200012000-00002","article-title":"Comparative abuse liability of intravenously administered remifentanil and fentanyl","volume":"20","author":"Baylon","year":"2000","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103709_bib172","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.npp.1300596","article-title":"Mu-opioid self-administration vs passive administration in heroin abusers produces differential EEG activation","volume":"30","author":"Greenwald","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpet.2025.103709_bib173","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0022-3565(25)13068-1","article-title":"Comparative clinical pharmacology of short-acting Mu opioids in drug abusers","volume":"277","author":"Greenwald","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103709_bib174","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: receptor pharmacology, abuse potential, and implications for treatment","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103709_bib175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drugalcdep.2007.09.002","article-title":"Behavioral economic analysis of drug preference using multiple choice procedure data","volume":"93","author":"Greenwald","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.jpet.2025.103709_bib176","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00213-024-06557-1","article-title":"A dose-ranging study of the physiological and self-reported effects of repeated, rapid infusion of remifentanil in people with opioid use disorder and physical dependence on fentanyl","volume":"241","author":"Lile","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.jpet.2025.103709_bib177","article-title":"Old drugs and new challenges: a narrative review of nitazenes","volume":"15","author":"Pergolizzi","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.jpet.2025.103709_bib178","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/jat\/bkaa016","article-title":"Isotonitazene quantitation and metabolite discovery in authentic forensic casework","volume":"44","author":"Krotulski","year":"2020","journal-title":"J Anal Toxicol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103709_bib179","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","article-title":"Synthesis, chemical characterization, and \u03bc-opioid receptor activity assessment of the emerging group of \u201cnitazene\u201d 2-benzylbenzimidazole synthetic opioids","volume":"12","author":"Vandeputte","year":"2021","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103709_bib180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.123.002052","article-title":"Pharmacologic characterization of substituted nitazenes at \u03bc, \u03ba, and \u03b4 opioid receptors suggests high potential for toxicity","volume":"389","author":"Kozell","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.jpet.2025.103709_bib181","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s00213-023-06451-2","article-title":"Alkoxy chain length governs the potency of 2-benzylbenzimidazole \u201cnitazene\u201d opioids associated with human overdose","volume":"240","author":"Glatfelter","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpet.2025.103709_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110416","article-title":"Discriminative stimulus and antinociceptive effects of sixteen nitazene analogs in rodents","volume":"272","author":"Gatch","year":"2025","journal-title":"Neuropharmacology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:58:46Z","timestamp":1761850726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":178,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0022356525402225"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103709","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonpharmacological and pharmacological influences on opioid effects: A review of clinical research findings","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103709"}}